Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altitude Acquisition Corp.ALTU · Entity 114367 | Director | September 13, 2022 | September 23, 2022 |
| Astrana Health, Inc.AMEH · Entity 4538 | Director · Co-Chief Executive Officer | November 28, 2018 | December 01, 2018 |
| Cardio Diagnostics Holdings, Inc.CDIO · Entity 8239 | Director | January 23, 2024 | February 21, 2024 |
| General Purpose Acquisition Corp.GPAC · Entity 5958 | Director | December 02, 2025 | December 02, 2025 |
| Nutex Health Inc.NUTX · Entity 4803 | Director · President | March 19, 2026 | March 23, 2026 |
| Veraxa Biotech AGVRXA · Entity 184032 | Director | September 10, 2026 | September 29, 2026 |
| Veraxa Biotech AG - Post de-SPACVRXA · Entity 6310 | Director | June 09, 2026 | June 10, 2026 |
| Voyager Acquisition Corp./Cayman IslandsVACHU · Entity 88278 | Director | August 08, 2024 | August 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altitude Acquisition Corp.
Report date September 13, 2022 · Filed September 23, 2022
This filing explicitly reported no securities owned.
Astrana Health, Inc.
Report date November 28, 2018 · Filed December 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 524,438 |
Reported balance
After 2018-11-28 transaction · row 1
1 source rowRow 1 · 2018-11-28 · Sale · Disposed 35,000 · Balance 524,438 |
Cardio Diagnostics Holdings, Inc.
Report date January 23, 2024 · Filed February 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.11 · Expires 2034-01-23 | Direct | 502,195 |
Reported balance
After 2024-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-23 · Grant · Acquired 35,719 · Balance 502,195 |
General Purpose Acquisition Corp.
Report date December 02, 2025 · Filed December 02, 2025
This filing explicitly reported no securities owned.
Nutex Health Inc.
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,765 |
Reported balance
After 2026-03-19 transaction · row 1
1 source rowRow 1 · 2026-03-19 · Purchase · Acquired 252 · Balance 7,765 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-03-01 | Direct | 12,465 |
Reported balance
After 2026-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-10 · Exercise / conversion · Acquired 3,656 · Balance 12,465 F1: This Form 4 corrects the number of restricted stock units (RSUs) beneficially owned following the RSU grant reported in the reporting person's Form 4 filed on March 11, 2026 relating to a transaction dated March 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 corrects the number of restricted stock units (RSUs) beneficially owned following the RSU grant reported in the reporting person's Form 4 filed on March 11, 2026 relating to a transaction dated March 10, 2026.
Veraxa Biotech AG
Report date September 10, 2026 · Filed September 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 634,692 |
Reported balance
After 2026-09-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-10 · Purchase · Acquired 6,024 · Balance 634,692 F1: The reported securities reflect the forfeiture of 71,332 Ordinary Shares of Veraxa Biotech AG (the "Company"), par value CHF 1/113.25, for no additional consideration, in connection with the Company's business combination consummated on June 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities reflect the forfeiture of 71,332 Ordinary Shares of Veraxa Biotech AG (the "Company"), par value CHF 1/113.25, for no additional consideration, in connection with the Company's business combination consummated on June 10, 2026.
Veraxa Biotech AG - Post de-SPAC
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 700,000 |
Reported balance
Holding disclosure · report date 2026-06-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 700,000 |
Voyager Acquisition Corp./Cayman Islands
Report date August 08, 2024 · Filed August 09, 2024
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 29, 2026 20:10 UTC | Veraxa Biotech AG VRXA · Entity 184032 | PurchaseOrdinary Shares | 6,024 | $1.67 | $10,060.08 |
DisclosureSEC source: 0001829126-26-010557 · ownership.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 634,692 F1 · balance_after: The reported securities reflect the forfeiture of 71,332 Ordinary Shares of Veraxa Biotech AG (the "Company"), par value CHF 1/113.25, for no additional consideration, in connection with the Company's business combination consummated on June 10, 2026. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 17:21 UTC | Nutex Health Inc. NUTX · Entity 4803 | PurchaseCommon Stock | 252 | $94.07 | $23,706.22 |
DisclosureSEC source: 0001438327-26-000002 · primary_doc.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,765 Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 21:20 UTC | Nutex Health Inc. NUTX · Entity 4803 | Exercise / conversionRestricted Stock Units · Derivative | 3,656 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001438327-26-000001 · primary_doc.xml · derivative · entry 3 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,739 Underlying: Common Stock · 3,656 shares Expires 2029-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 11, 2026, the Reporting Person was granted 3,656 RSUs, which vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029. F3 · derivative.expiration_date: On March 11, 2026, the Reporting Person was granted 3,656 RSUs, which vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029. F3 · derivative.underlying_shares: On March 11, 2026, the Reporting Person was granted 3,656 RSUs, which vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 21:20 UTC | Nutex Health Inc. NUTX · Entity 4803 | Tax withholdingCommon Stock | 3,274 | $86.22 | $282,292.14 |
DisclosureSEC source: 0001438327-26-000001 · primary_doc.xml · nonDerivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,513 F2 · shares: Of the 6,293 shares issued subsequent to vesting, 3,274 shares were sold to cover tax withholding obligations. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 21:20 UTC | Nutex Health Inc. NUTX · Entity 4803 | Exercise / conversionCommon Stock | 6,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001438327-26-000001 · primary_doc.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 10, 2026 Filed Mar 23, 2026 17:21 UTC | Nutex Health Inc. NUTX · Entity 4803 | Exercise / conversionRestricted Stock Units · Derivative | 3,656 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001438327-26-000002 · primary_doc.xml · derivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,465 Underlying: Common Stock · 3,656 shares Expires 2029-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 corrects the number of restricted stock units (RSUs) beneficially owned following the RSU grant reported in the reporting person's Form 4 filed on March 11, 2026 relating to a transaction dated March 10, 2026. F1 · balance_after: This Form 4 corrects the number of restricted stock units (RSUs) beneficially owned following the RSU grant reported in the reporting person's Form 4 filed on March 11, 2026 relating to a transaction dated March 10, 2026. Read SEC document |
| April 04, 2025 Filed Apr 14, 2025 17:55 UTC | Nutex Health Inc. NUTX · Entity 4803 | Tax withholdingCommon Stock | 1,072 | $72.10 | $77,288.20 |
DisclosureSEC source: 0001486189-25-000011 · primary_doc.xml · nonDerivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,422 F2 · shares: Of the shares 3,776 issued subsequent to vesting, 1,072 shares were sold to cover tax withholding obligations. Read SEC document |
| March 10, 2025 Filed Apr 14, 2025 17:55 UTC | Nutex Health Inc. NUTX · Entity 4803 | Exercise / conversionRestricted Stock Units · Derivative | 7,551 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001486189-25-000011 · primary_doc.xml · derivative · entry 3 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,102 Underlying: Common Stock · 7,551 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 10, 2025, the Reporting Person was granted [Col x] RSUs, which vest in three equal installments on March 1, 2026, March 1, 2027, and March 1, 2028. F3 · derivative.expiration_date: On March 10, 2025, the Reporting Person was granted [Col x] RSUs, which vest in three equal installments on March 1, 2026, March 1, 2027, and March 1, 2028. Read SEC document |
| March 01, 2025 Filed Apr 14, 2025 17:55 UTC | Nutex Health Inc. NUTX · Entity 4803 | Exercise / conversionCommon Stock | 3,776 | $0.00 | $0.00 |
DisclosureSEC source: 0001486189-25-000011 · primary_doc.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 28, 2024 Filed Jun 28, 2024 15:47 UTC Amendment | Nutex Health Inc. NUTX · Entity 4803 | GrantRestricted Stock Unit · Derivative | 113,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001486189-24-000031 · primary_doc.xml · derivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,265 Underlying: Common Stock · 113,265 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the issuer's common stock, $0.001 par value, upon vesting. F2 · derivative.exercise_date: Pursuant to the Restricted Stock Unit Agreement by and between the issuer and Dr. Hosseinion dated June 28, 2024, the 113,265 RSUs granted to Dr. Hosseinion will vest in three equal installments vesting 1/3 each on March 1, 2025, March 1, 2026 and March 1, 2027. F2 · derivative.expiration_date: Pursuant to the Restricted Stock Unit Agreement by and between the issuer and Dr. Hosseinion dated June 28, 2024, the 113,265 RSUs granted to Dr. Hosseinion will vest in three equal installments vesting 1/3 each on March 1, 2025, March 1, 2026 and March 1, 2027. F1 · derivative.underlying_shares: Each RSU represents a contingent right to receive one share of the issuer's common stock, $0.001 par value, upon vesting. Read SEC document |
| June 28, 2024 Filed Jun 28, 2024 15:42 UTC | Nutex Health Inc. NUTX · Entity 4803 | GrantRestricted Stock Unit · Derivative | 113,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001486189-24-000030 · primary_doc.xml · derivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,265 Underlying: Common Stock · 113,265 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the issuer's common stock, $0.001 par value, upon vesting. F2 · derivative.exercise_date: Pursuant to the Restricted Stock Unit Agreement by and between the issuer and Dr. Hosseinion dated June 28, 2024, the 113,265 RSUs granted to Dr. Hosseinion will vest in three equal installments vesting 1/3 each on March 1, 2025, March 1, 2026 and March 1, 2027. F2 · derivative.expiration_date: Pursuant to the Restricted Stock Unit Agreement by and between the issuer and Dr. Hosseinion dated June 28, 2024, the 113,265 RSUs granted to Dr. Hosseinion will vest in three equal installments vesting 1/3 each on March 1, 2025, March 1, 2026 and March 1, 2027. F1 · balance_after: Each RSU represents a contingent right to receive one share of the issuer's common stock, $0.001 par value, upon vesting. Read SEC document |
| January 23, 2024 Filed Feb 21, 2024 20:03 UTC | Cardio Diagnostics Holdings, Inc. CDIO · Entity 8239 | GrantStock Options (Right to Buy) · Derivative | 35,719 | $2.11 Strike: $2.11 | $75,367.09 |
DisclosureSEC source: 0001486189-24-000011 · primary_doc.xml · derivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,195 Underlying: Common Stock · 35,719 shares Expires 2034-01-23 Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 20:38 UTC | Nutex Health Inc. NUTX · Entity 4803 | GiftWarrants · Derivative | 10,795 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001486189-23-000036 · primary_doc.xml · derivative · entry 3 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,795 Underlying: Common Stock · 10,795 shares Expires 2024-12-31 Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 20:38 UTC | Nutex Health Inc. NUTX · Entity 4803 | GiftStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001486189-23-000036 · primary_doc.xml · derivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,609,779 Underlying: Common Stock · 50,000 shares Expires 2030-01-27 F1 · price: The options were granted pursuant to the Issuers 2019 Omnibus Equity Incentive Plan and Amended and Restated Nutex Health Inc. 2023 Equity Incentive Plan. F1 · balance_after: The options were granted pursuant to the Issuers 2019 Omnibus Equity Incentive Plan and Amended and Restated Nutex Health Inc. 2023 Equity Incentive Plan. Read SEC document |
| September 22, 2023 Filed Oct 5, 2023 20:38 UTC | Nutex Health Inc. NUTX · Entity 4803 | GiftCommon Stock | 141,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001486189-23-000036 · primary_doc.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,678 Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:49 UTC | Cardio Diagnostics Holdings, Inc. CDIO · Entity 8239 | GrantStock Options (Right to Buy) · Derivative | 123,750 | $1.26 Strike: $1.26 | $155,925.00 |
DisclosureSEC source: 0001486189-23-000013 · primary_doc.xml · derivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,750 Underlying: Common Stock · 123,750 shares Expires 2033-06-23 Read SEC document |
| September 15, 2022 Filed Sep 17, 2022 01:00 UTC | Nutex Health Inc. NUTX · Entity 4803 | SaleCommon Stock | 70,000 | $2.36 | $165,200.00 |
DisclosureSEC source: 0001486189-22-000019 · primary_doc.xml · nonDerivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,975 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.38 to $2.30, inclusive. The reporting person undertakes to provide to Nutex Health, Inc., any security holder of Nutex Health, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| September 14, 2022 Filed Sep 17, 2022 01:00 UTC | Nutex Health Inc. NUTX · Entity 4803 | SaleCommon Stock | 130,000 | $2.46 | $319,800.00 |
DisclosureSEC source: 0001486189-22-000019 · primary_doc.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,975 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.41, inclusive. The reporting person undertakes to provide to Nutex Health, Inc., any security holder of Nutex Health, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| September 09, 2022 Filed Sep 10, 2022 00:56 UTC | Nutex Health Inc. NUTX · Entity 4803 | SaleCommon Stock | 150,000 | $2.84 | $426,360.00 |
DisclosureSEC source: 0001486189-22-000017 · primary_doc.xml · nonDerivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,975 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.80 to $2.98, inclusive. The reporting person undertakes to provide to Nutex Health, Inc., any security holder of Nutex Health, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| September 07, 2022 Filed Sep 10, 2022 00:56 UTC | Nutex Health Inc. NUTX · Entity 4803 | SaleCommon Stock | 100,000 | $2.99 | $299,000.00 |
DisclosureSEC source: 0001486189-22-000017 · primary_doc.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598,975 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.99 to $3.20, inclusive. The reporting person undertakes to provide to Nutex Health, Inc., any security holder of Nutex Health, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| September 06, 2022 Filed Sep 6, 2022 20:52 UTC | Nutex Health Inc. NUTX · Entity 4803 | SaleCommon Stock | 100,000 | $2.79 | $278,830.00 |
DisclosureSEC source: 0001486189-22-000016 · primary_doc.xml · nonDerivative · entry 3 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,975 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.7500 to $2.8271, inclusive. The reporting person undertakes to provide to Nutex Health, Inc., any security holder of Nutex Health, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:52 UTC | Nutex Health Inc. NUTX · Entity 4803 | SaleCommon Stock | 180,000 | $2.48 | $447,048.00 |
DisclosureSEC source: 0001486189-22-000016 · primary_doc.xml · nonDerivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 798,975 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.4009 to $2.5031, inclusive. The reporting person undertakes to provide to Nutex Health, Inc., any security holder of Nutex Health, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:52 UTC | Nutex Health Inc. NUTX · Entity 4803 | SaleCommon Stock | 70,000 | $2.56 | $179,480.00 |
DisclosureSEC source: 0001486189-22-000016 · primary_doc.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 978,975 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.5445 to $2.5840, inclusive. The reporting person undertakes to provide to Nutex Health, Inc., any security holder of Nutex Health, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| May 05, 2022 Filed May 11, 2022 16:46 UTC | Nutex Health Inc. NUTX · Entity 4803 | GiftCommon Stock | 102,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001486189-22-000013 · primary_doc.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,048,675 Read SEC document |
| April 01, 2022 Filed Apr 8, 2022 18:12 UTC | Nutex Health Inc. NUTX · Entity 4803 | GrantDirector Stock Option (right to buy) · Derivative | 1,900,000 | $2.75 Strike: $2.75 | $5,225,000.00 |
DisclosureSEC source: 0001486189-22-000001 · primary_doc.xml · derivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,723,590 Underlying: Common Stock · 1,900,000 shares Expires 2032-04-01 Read SEC document |
| February 25, 2021 Filed Dec 21, 2021 18:10 UTC | Nutex Health Inc. CLNH · Entity 4803 | OtherCommon Stock | 894,209 | $2.04 | $1,824,186.36 |
DisclosureSEC source: 0001486189-21-000013 · primary_doc.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151,563 F1 · kind: Acquired as per merger exchange. Read SEC document |
| January 28, 2021 Filed Feb 3, 2021 19:55 UTC | Nutex Health Inc. CLNH · Entity 4803 | Grant600,000 · Derivative | 600,000 | $1.61 Strike: $1.61 | $966,000.00 |
DisclosureSEC source: 0001486189-21-000004 · primary_doc.xml · derivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 600,000 shares Expires 2031-01-27 F1 · derivative.expiration_date: Vested upon closing of merger. Read SEC document |
| August 12, 2020 Filed Sep 9, 2020 14:02 UTC Amendment | Nutex Health Inc. CLNH · Entity 4803 | PurchaseCommon Stock | 31,746 | $20,000.00 | $634,920,000.00 |
DisclosureSEC source: 0001486189-20-000017 · primary_doc.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,521 F1 · balance_after: Does not include 200,000 options and 21,590 warrants previously reported. Read SEC document |
| August 12, 2020 Filed Sep 9, 2020 13:05 UTC | Nutex Health Inc. CLNH · Entity 4803 | Disposition to issuerCommon Stock | 31,746 | $20,000.00 | $634,920,000.00 |
DisclosureSEC source: 0001486189-20-000011 · primary_doc.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,521 F1 · balance_after: Does not include 200,000 options and 21,590 warrants previously reported Read SEC document |
| May 11, 2020 Filed Jun 17, 2020 18:56 UTC | Nutex Health Inc. CLNH · Entity 4803 | GrantDirector Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001486189-20-000007 · primary_doc.xml · derivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,590 Underlying: Common Stock · 100,000 shares Expires 2027-05-11 Read SEC document |
| January 27, 2020 Filed Apr 28, 2020 15:33 UTC Amendment | Nutex Health Inc. CLNH · Entity 4803 | GrantDirector Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001438327-20-000002 · primary_doc.xml · derivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,590 Underlying: Common Stock · 100,000 shares Expires 2030-01-27 F1 · balance_after: Amended to correct number of derivative securities beneficially owned following reported transaction. Read SEC document |
| January 27, 2020 Filed Apr 28, 2020 14:35 UTC | Nutex Health Inc. CLNH · Entity 4803 | PurchaseDirector Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001438327-20-000001 · primary_doc.xml · derivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-01-27 Read SEC document |
| January 27, 2020 Filed Dec 21, 2021 18:10 UTC | Nutex Health Inc. CLNH · Entity 4803 | PurchaseDirector Stock Option (right to buy) · Derivative | 800,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001486189-21-000013 · primary_doc.xml · derivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires not disclosed F2 · derivative.exercise_price: 100,000 options at $1.50 exercise date 01/27/2020 expiration date 01/27/2030 100,000 options at $1.50 exercise date 05/11/2020 expiration date 05/11/2027 600,000 options at $1.61 exercise date 01/28/2021 expiration date 01/28/2030 F2 · date: 100,000 options at $1.50 exercise date 01/27/2020 expiration date 01/27/2030 100,000 options at $1.50 exercise date 05/11/2020 expiration date 05/11/2027 600,000 options at $1.61 exercise date 01/28/2021 expiration date 01/28/2030 F2 · price: 100,000 options at $1.50 exercise date 01/27/2020 expiration date 01/27/2030 100,000 options at $1.50 exercise date 05/11/2020 expiration date 05/11/2027 600,000 options at $1.61 exercise date 01/28/2021 expiration date 01/28/2030 F2 · derivative.exercise_date: 100,000 options at $1.50 exercise date 01/27/2020 expiration date 01/27/2030 100,000 options at $1.50 exercise date 05/11/2020 expiration date 05/11/2027 600,000 options at $1.61 exercise date 01/28/2021 expiration date 01/28/2030 F2 · derivative.expiration_date: 100,000 options at $1.50 exercise date 01/27/2020 expiration date 01/27/2030 100,000 options at $1.50 exercise date 05/11/2020 expiration date 05/11/2027 600,000 options at $1.61 exercise date 01/28/2021 expiration date 01/28/2030 Read SEC document |
| March 19, 2019 Filed Dec 21, 2021 18:10 UTC | Nutex Health Inc. CLNH · Entity 4803 | PurchaseWarrants to Puchase common stock · Derivative | 21,590 | $6.67 Strike: $6.67 | $144,005.30 |
DisclosureSEC source: 0001486189-21-000013 · primary_doc.xml · derivative · entry 3 Hosseinion Warren · CIK 0001438327 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,590 Underlying: Common Stock · 21,590 shares Expires 2024-12-31 Read SEC document |
| November 28, 2018 Filed Dec 1, 2018 00:06 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 35,000 | $16.60 | $581,000.00 |
DisclosureSEC source: 0001567619-18-007189 · doc1.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,438 Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 01:15 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 30,000 | $17.31 | $519,300.00 |
DisclosureSEC source: 0001567619-18-007081 · doc1.xml · nonDerivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,438 Read SEC document |
| November 26, 2018 Filed Nov 29, 2018 01:15 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 20,000 | $17.91 | $358,200.00 |
DisclosureSEC source: 0001567619-18-007081 · doc1.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,438 Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 00:21 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 20,000 | $17.07 | $341,400.00 |
DisclosureSEC source: 0001567619-18-006971 · doc1.xml · nonDerivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,438 Read SEC document |
| November 21, 2018 Filed Nov 27, 2018 00:21 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 30,000 | $16.21 | $486,300.00 |
DisclosureSEC source: 0001567619-18-006971 · doc1.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629,438 Read SEC document |
| November 20, 2018 Filed Nov 22, 2018 00:14 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 20,000 | $17.58 | $351,600.00 |
DisclosureSEC source: 0001567619-18-006863 · doc1.xml · nonDerivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,438 Read SEC document |
| November 19, 2018 Filed Nov 22, 2018 00:14 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 20,000 | $18.97 | $379,400.00 |
DisclosureSEC source: 0001567619-18-006863 · doc1.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679,438 Read SEC document |
| August 30, 2018 Filed Aug 31, 2018 22:00 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 7,900 | $15.76 | $124,504.00 |
DisclosureSEC source: 0001567619-18-002000 · doc1.xml · nonDerivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 699,438 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 22:00 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 15,000 | $16.03 | $240,450.00 |
DisclosureSEC source: 0001567619-18-002000 · doc1.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 707,338 Read SEC document |
| August 28, 2018 Filed Aug 29, 2018 23:06 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 15,000 | $16.65 | $249,750.00 |
DisclosureSEC source: 0001567619-18-001892 · doc1.xml · nonDerivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,338 Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 23:06 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 15,000 | $17.35 | $260,250.00 |
DisclosureSEC source: 0001567619-18-001892 · doc1.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737,338 Read SEC document |
| August 24, 2018 Filed Aug 27, 2018 23:17 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 15,000 | $16.47 | $247,050.00 |
DisclosureSEC source: 0001567619-18-001822 · doc1.xml · nonDerivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,338 Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 23:17 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 18,000 | $15.97 | $287,460.00 |
DisclosureSEC source: 0001567619-18-001822 · doc1.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 767,338 Read SEC document |
| August 22, 2018 Filed Aug 23, 2018 23:00 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 15,000 | $16.32 | $244,800.00 |
DisclosureSEC source: 0001567619-18-001759 · doc1.xml · nonDerivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 785,338 Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 23:00 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 15,000 | $16.73 | $250,950.00 |
DisclosureSEC source: 0001567619-18-001759 · doc1.xml · nonDerivative · entry 1 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,338 Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 23:03 UTC | Astrana Health, Inc. AMEH · Entity 4538 | SaleCommon Stock | 12,000 | $17.75 | $213,000.00 |
DisclosureSEC source: 0001567619-18-001588 · doc1.xml · nonDerivative · entry 2 Hosseinion Warren · CIK 0001438327 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 815,338 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.